Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 10:42AM ET
1.32
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-0.10 Insider Own14.39% Shs Outstand43.92M Perf Week2.33%
Market Cap58.83M Forward P/E- EPS next Y-0.74 Insider Trans0.00% Shs Float38.16M Perf Month14.78%
Income-4.09M PEG- EPS next Q-0.43 Inst Own42.98% Short Float0.33% Perf Quarter6.45%
Sales0.00M P/S- EPS this Y101.86% Inst Trans-6.05% Short Ratio0.43 Perf Half Y-13.73%
Book/sh2.31 P/B0.57 EPS next Y-1744.44% ROA-3.41% Short Interest0.13M Perf Year-5.71%
Cash/sh2.38 P/C0.55 EPS next 5Y- ROE-4.07% 52W Range0.57 - 1.70 Perf YTD-2.94%
Dividend Est.- P/FCF- EPS past 5Y-25.34% ROI-3.97% 52W High-22.35% Beta1.23
Dividend TTM- Quick Ratio14.44 Sales past 5Y0.00% Gross Margin- 52W Low131.58% ATR (14)0.06
Dividend Ex-Date- Current Ratio14.44 EPS Y/Y TTM96.23% Oper. Margin0.00% RSI (14)51.75 Volatility3.76% 5.42%
Employees78 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price2.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q7.64% Payout- Rel Volume0.27 Prev Close1.32
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsAug 10 BMO Avg Volume293.45K Price1.32
SMA201.77% SMA50-1.61% SMA200-2.58% Trades Volume17,749 Change0.00%
Date Action Analyst Rating Change Price Target Change
Dec-18-23Downgrade Mizuho Buy → Neutral
Jan-05-22Downgrade BTIG Research Buy → Neutral
Nov-19-21Downgrade Morgan Stanley Overweight → Equal-Weight $24 → $7
Jun-15-21Initiated BTIG Research Buy $23
May-27-21Initiated Needham Buy $28
Mar-09-21Initiated Barclays Overweight $23
Mar-02-21Initiated Stifel Hold $14
Nov-11-20Initiated Berenberg Buy
Mar-31-20Downgrade H.C. Wainwright Buy → Neutral $13
Jun-27-19Initiated Mizuho Buy $28
Feb-27-24 10:50AM
Feb-01-24 02:25PM
Jan-31-24 10:40AM
06:42AM
Jan-30-24 02:52PM
02:38PM Loading…
02:38PM
08:00AM
Nov-08-23 09:40AM
Oct-23-23 09:40AM
Oct-06-23 09:40AM
Jul-13-23 07:08AM
Jul-12-23 07:00AM
Jun-12-23 07:00AM
May-22-23 07:00AM
May-18-23 02:53PM
07:00AM Loading…
07:00AM
May-11-23 07:00AM
May-01-23 07:30AM
Mar-23-23 07:00AM
Mar-03-23 07:00AM
Feb-09-23 07:00AM
Jan-05-23 07:00AM
Dec-07-22 07:30AM
Nov-17-22 07:00AM
Nov-08-22 07:00AM
Nov-07-22 07:00AM
Nov-03-22 07:00AM
Oct-27-22 07:00AM
Oct-25-22 07:00AM
Oct-18-22 07:00AM
07:00AM Loading…
Oct-11-22 07:00AM
Oct-06-22 07:00AM
Sep-27-22 07:00AM
Sep-20-22 07:00AM
Sep-14-22 07:28AM
Sep-08-22 07:00AM
Aug-31-22 07:00AM
Aug-09-22 07:00AM
Aug-04-22 07:00AM
Aug-01-22 07:00AM
Jul-13-22 07:00AM
Jul-06-22 07:00AM
May-18-22 03:12PM
12:41PM
07:00AM
May-17-22 12:15PM
07:00AM
May-16-22 07:00AM
May-10-22 07:00AM
May-06-22 07:00AM
May-03-22 07:00AM
Apr-06-22 12:36PM
07:00AM
Apr-05-22 12:54PM
07:00AM
Mar-17-22 07:00AM
Mar-01-22 07:00AM
Feb-21-22 12:14PM
Feb-09-22 12:55PM
07:00AM
Feb-04-22 07:00AM
Feb-03-22 10:00AM
Feb-01-22 07:00AM
Jan-28-22 07:00AM
Jan-27-22 07:00AM
Jan-25-22 10:00AM
Jan-07-22 10:00AM
Jan-06-22 07:00AM
Jan-04-22 02:28PM
09:07AM
07:57AM
07:00AM
Dec-07-21 07:00AM
Dec-04-21 06:25AM
Nov-24-21 07:00AM
Nov-09-21 07:00AM
Nov-08-21 07:00AM
Nov-05-21 07:00AM
Nov-04-21 07:00AM
Nov-03-21 07:00AM
Oct-26-21 07:00AM
Oct-20-21 07:00AM
Oct-19-21 07:00AM
Oct-06-21 07:00AM
Oct-05-21 07:00AM
Sep-05-21 08:25AM
Sep-03-21 04:01PM
Sep-01-21 07:00AM
Aug-05-21 07:00AM
Aug-04-21 07:00AM
Aug-02-21 07:00AM
Jul-12-21 08:49AM
Jul-08-21 07:00AM
Jun-27-21 01:39PM
Jun-17-21 09:43AM
Jun-10-21 07:00AM
Jun-07-21 01:37PM
Jun-04-21 07:00AM
May-13-21 07:00AM
May-12-21 08:32AM
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Avruch StevenChief Legal OfficerFeb 01Option Exercise0.0032,834032,834Feb 05 07:56 PM
Ostrowski ErikInterim CEO, President and CFOFeb 01Option Exercise0.0040,084042,384Feb 05 07:57 PM
Ridha EssraChief Medical OfficerFeb 01Option Exercise0.0032,834032,834Feb 05 07:59 PM
Golipour AzadehChief Technology OfficerFeb 01Option Exercise0.0037,334068,104Feb 05 08:01 PM